Global Drugs for Vulvovaginal Candidiasis Market Forecast to 2025 Detailed in New Research Report

Market Analysis Research Report on “Global Drugs for Vulvovaginal Candidiasis Market” has been added to orbis research database.

This report researches the worldwide Drugs for Vulvovaginal Candidiasis market size (value, capacity, production and consumption) in key regions like United States, Europe, Asia Pacific (China, Japan) and other regions.

This study categorizes the Global Drugs for Vulvovaginal Candidiasis Market breakdown data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.

The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.

Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.

In 2017, the global Drugs for Vulvovaginal Candidiasis market size was 770 million US$ and is forecast to 860 million US in 2025, growing at a CAGR of 1.5% from 2018. The objectives of this study are to define, segment, and project the size of the Drugs for Vulvovaginal Candidiasis market based on company, product type, application and key regions.

Request a sample of this report @ .

The various contributors involved in the value chain of Drugs for Vulvovaginal Candidiasis include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Drugs for Vulvovaginal Candidiasis include



J & J


Bristol-Myers Squibb




Cisen Pharmaceutical

Kingyork Group

Market Size Split by Type

By Formulation Types




By Drugs Types






Market Size Split by Application

Hospital & Clinic


Place a Direct Purchase Order on this report @ .

About Us:
Orbis Research ( is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID:

Post a Comment